Venetoclax Combinations Show Promise in High-Risk MDS Despite Trial Setback
A narrative review of ASH 2025 and EHA 2026 data suggests venetoclax combinations raise response rates in high-risk myelodysplastic syndromes, ...
Tag: EHA 2026
POPULAR NEWS
-
Systematic review maps end-of-life psychosocial and spiritual needs in physical disability
-
Text Message Campaign Reached Only a Third of Patients Overdue for Colorectal Cancer Screening
-
FOXO1 Emerges as Candidate Regulator and Biomarker in Hip Dysplasia
-
Regulators, developers and clinicians in Shenzhen voice concerns over medical AI governance